short T1/2 dual orexin 1/2 receptor antagonist

in clinical dev. for insomnia (Ph. II)

from ligand-based drug design

Bioorg. Med. Chem., Apr. 11, 2020

Taisho Pharmaceutical Co., Saitama, JP

ORN0829

ORN0829 is a dual inhibitor of orexins 1 and 2, designed to have a relatively short half life in humans for application in insomnia (to reduce side effects after waking…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: